Candel Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Candel Therapeutics (CADL).

Price Target Range — 8 Quarters

Analyst Consensus — 9 Analysts

9Buy

Consensus RatingBuy# Analysts9Avg. Consensus PT$20Upside to Avg. PT+125.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 21, 2026	B of A Securities	Alec Stranahan	Upgrade	Neutral→Buy	$12→$18
Aug 14, 2026	B of A Securities	Alec Stranahan	PT Raise	Neutral	$9→$12
Aug 13, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$23
Jul 13, 2026	Stifel	Stephen Willey	Initiate	Buy	$22
Apr 20, 2026	Cantor Fitzgerald	—	Initiate	Overweight	—
Mar 18, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$22→$26
Mar 13, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$24→$22
Mar 13, 2026	Canaccord Genuity	John Newman	Maintained	Buy	$25
Dec 8, 2025	Stephens & Co.	Sudan Loganathan	Maintained	Overweight	$15
Nov 21, 2025	Freedom Broker	Ilya Zubkov	PT Raise	Buy	$13→$14
Nov 14, 2025	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$25→$24
Oct 28, 2025	Stephens & Co.	Sudan Loganathan	Initiate	Overweight	$15
Oct 21, 2025	LifeSci Capital	—	Initiate	Outperform	$16
Sep 29, 2025	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$23
Sep 3, 2025	B of A Securities	Alec Stranahan	Downgrade	Buy→Neutral	$13→$7
Jul 14, 2025	Freedom Broker	Ilya Zubkov	Initiate	Buy	$13
Jun 30, 2025	HC Wainwright & Co.	Andrew Fein	Assumes	Buy	$23
Apr 11, 2025	HC Wainwright & Co.	Vernon Bernardino	Maintained	Buy	$19
Mar 14, 2025	HC Wainwright & Co.	Vernon Bernardino	Maintained	Buy	$19
Feb 26, 2025	Canaccord Genuity	John Newman	PT Raise	Buy	$20→$25

More with Benzinga EdgeGet Access

Analyst Ratings News

This Macerich Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Analysts upgraded MAC, INVH, CIEN, AMH and CADL, raising ratings and several price targets.

Avi Kapoor

PRO
B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18

B of A Securities analyst Alec Stranahan upgrades Candel Therapeutics (NASDAQ:CADL) from Neutral to Buy and raises the price target from $12 to $18.

Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

B of A Securities analyst Alec Stranahan maintains Candel Therapeutics (NASDAQ:CADL) with a Neutral and raises the price target from $9 to $12.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ:CADL) with a Buy and maintains $23 price target.

Benzinga Newsdesk

PRO
Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $22.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating

Cantor Fitzgerald initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Overweight rating.

Benzinga Newsdesk

Candel Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Candel Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Macerich Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

PRO
B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18

PRO
B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

PRO
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

PRO
Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

PRO
Cantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating

People Also Watch

People Also Watch

Candel Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Candel Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Macerich Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

PROB of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18

PROB of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

PROHC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

PROStifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

PROCantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating

People Also Watch

People Also Watch

PRO
B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18

PRO
B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

PRO
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

PRO
Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

PRO
Cantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating